Skip to main content

Table 1 Proportion of addenda by indication area

From: Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree

Indications

Early benefit assessments by indication (N)

Addenda for early benefit assessments by indication (N)

Proportion of addenda within indication (%)

Overall proportion by indication (%)

Subgroups in addenda by indication (N)

Overall proportion of subgroups by indication (%)

Oncology

96

40

42%

44%

56

45%

Metabolic disorders

40

16

40%

18%

18

15%

Infectious diseases

25

12

48%

13%

22

18%

Others

39

11

28%

12%

16

13%

Neurology

16

7

44%

8%

7

6%

Respiratory diseases

13

4

31%

5%

5

4%